Physicians Can Be Trained to Interpret Axumin PET Images of Recurrent Prostate Cancer, Study Finds

Physicians Can Be Trained to Interpret Axumin PET Images of Recurrent Prostate Cancer, Study Finds
A study supported by Blue Earth Diagnostics showed that physicians can be trained to successfully interpret Axumin PET scan images of patients with suspected recurrence of prostate cancer. Axumin is the first F-18 PET imaging agent approved for use in men with suspected recurrent prostate cancer, based on increased blood levels of PSA following treatment. The study, “Reader training for the re-staging of biochemically recurrent prostate cancer using fluciclovine (18F) PET/CT,” appeared in The Journal of Nuclear Medicine. The Phase 3 study (NCT02680041) was designed to train readers without any experience in reading Axumin PET/CT images to interpret images from patients with recurrent prostate cancer with acceptable diagnostic performance and reproducibility. It next assessed the ability of readers to accurately interpret Axumin images and compared it to reader concordance in other data, such as biopsies and clinical follow-up. The study included 121 images from 110 patients. Readers were trained to conduct
Subscribe or to access all post and page content.

Tagged , , , , .

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

Leave a Comment

Your email address will not be published. Required fields are marked *